NO930218L - Materiale som gir forbedret fjerning av bioaktive substanser fra blodstroemmen - Google Patents

Materiale som gir forbedret fjerning av bioaktive substanser fra blodstroemmen

Info

Publication number
NO930218L
NO930218L NO93930218A NO930218A NO930218L NO 930218 L NO930218 L NO 930218L NO 93930218 A NO93930218 A NO 93930218A NO 930218 A NO930218 A NO 930218A NO 930218 L NO930218 L NO 930218L
Authority
NO
Norway
Prior art keywords
materials
bioactive substances
provide improved
blood stream
improved removal
Prior art date
Application number
NO93930218A
Other languages
English (en)
Norwegian (no)
Other versions
NO930218D0 (no
Inventor
Johan Selmer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO930218D0 publication Critical patent/NO930218D0/no
Publication of NO930218L publication Critical patent/NO930218L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
NO93930218A 1990-07-24 1993-01-22 Materiale som gir forbedret fjerning av bioaktive substanser fra blodstroemmen NO930218L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK176290A DK176290D0 (da) 1990-07-24 1990-07-24 Terapeutisk og diagnostisk praeparat
PCT/DK1991/000215 WO1992001469A1 (en) 1990-07-24 1991-07-24 A composition providing improved clearance of bioactive substances from the bloodstream

Publications (2)

Publication Number Publication Date
NO930218D0 NO930218D0 (no) 1993-01-22
NO930218L true NO930218L (no) 1993-03-24

Family

ID=8107861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930218A NO930218L (no) 1990-07-24 1993-01-22 Materiale som gir forbedret fjerning av bioaktive substanser fra blodstroemmen

Country Status (11)

Country Link
EP (1) EP0540588B1 (ja)
JP (1) JPH05509092A (ja)
AT (1) ATE123951T1 (ja)
AU (1) AU659092B2 (ja)
CA (1) CA2087971A1 (ja)
DE (1) DE69110679T2 (ja)
DK (2) DK176290D0 (ja)
FI (1) FI930269A7 (ja)
GR (1) GR3017362T3 (ja)
NO (1) NO930218L (ja)
WO (1) WO1992001469A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
KR100452125B1 (ko) * 2002-07-30 2004-10-12 주식회사 바이오알앤즈 음식물쓰레기의 발효 소멸화 능력을 보유한 신규한 균주바실러스 서브틸리스 ｂｒｄ－００７ 및 이를 이용한음식물 쓰레기의 발효 소멸화용 미생물제제
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484198D1 (de) * 1983-07-29 1991-04-04 Milton David Goldenberg Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) * 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
NO930218D0 (no) 1993-01-22
AU659092B2 (en) 1995-05-11
DK0540588T3 (da) 1995-11-06
DK176290D0 (da) 1990-07-24
AU8282891A (en) 1992-02-18
FI930269L (fi) 1993-03-22
JPH05509092A (ja) 1993-12-16
WO1992001469A1 (en) 1992-02-06
CA2087971A1 (en) 1992-01-25
FI930269A7 (fi) 1993-03-22
EP0540588A1 (en) 1993-05-12
ATE123951T1 (de) 1995-07-15
DE69110679T2 (de) 1995-11-09
DE69110679D1 (de) 1995-07-27
FI930269A0 (fi) 1993-01-22
EP0540588B1 (en) 1995-06-21
GR3017362T3 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
DE3069944D1 (en) Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them
MX9204767A (es) Nuevos peptidos isostericos, proceso para su preparacion y composicion farmaceutica que los contiene
DK162630C (da) Hurtigt oploeselige ensartede laegemiddelpraeparater indeholdende triamteren eller metolazon og fremgangsmaade til fremstilling heraf.
ATE2616T1 (de) 1-aryl-2-acylamido-3-fluor-1-propanole, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
IL53594A (en) Biological cells comprising pharmaceutically active substances and additives controlling their release from the cells,their preparation and pharmaceutical compositions containing them
DK135564B (da) Apparat til anvendelse ved medicinsk eller kirurgisk behandling.
DK302383D0 (da) Tekstilmateriale og dets anvendelse til beholdere for pulverformede eller granulerede materialer
IL56581A (en) 6-substituted-8-(methoxymethyl)or(methylmercaptomethyl)ergolines and ergolenes,their preparation and pharmaceutical compositions containing them
IT1232149B (it) Composizione farmaceutica contenente ranitidina, e metodo per prepararla
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
DK560289A (da) Fluoxetin-analoge, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende saadanne
DE2963446D1 (en) New lactyl tetrapeptide, processes for preparation thereof and pharmaceutical compositions containing it
NO930218L (no) Materiale som gir forbedret fjerning av bioaktive substanser fra blodstroemmen
DE3066076D1 (en) Gravity feed stream splitter for splitting particulate material or for splitting and spreading particulate material, especially for use in particulate material separators
ATE7139T1 (de) N-aryl-n'-imidazol-2-yl-harnstoffe, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HRP20000781B1 (hr) Šumeći pripravci
IT8026672A0 (it) Derivati peptidici, procedimento per prepararli e relative composizioni farmaceutiche.
YU48978B (sh) Postupak za dobijanje preparata koji sadrži trandolapril i verapamil
NL7909200A (nl) N-gesubstitueerde trifluorethylaminen, farmaceutische preparaten met als werkzaam bestanddeel een dergelijk n-gesubstitueerd trifluorethylamine erin, alsmede werkwijzen voor de bereiding van de werkzame bestand- delen.
DK306784D0 (da) Fremgangsmaade til udvinding af organiske stoffer fra gasser ved adsorption og paafoelgende uskadeliggoerelse ved forbraending
LU81369A1 (de) Lagerbestaendige,schnell wirkende tablette zur bekaempfung von ueberwiegend in unterirdischen bauen lebenden wirbeltieren
NL7608429A (nl) Werkwijze voor het omzetten van fijnverdeelde, zwelbare celluloseethers in een gemakkelijk verder verwerkbaar materiaal.
NO900337L (no) Fremgangsmaate og anordning for aa overfoere utlutningsbare substanser i avfallsmateriale til gass eller utlutningsstabile forbindelser.
DK21379A (da) Oploesningsmiddelbaerer for terapeutica og dens anvendelse i farmaceutiske kompositioner